Cloning of chick cellular retinol-binding protein, type II and comparison to that of some mammals: expression of the gene at different developmental stages, and possible involvement of RXRs and PPAR

Developmental changes in gene expressions of β-carotene cleavage enzyme and retinoic acid synthesizing enzymes in the chick duodenum

Vitamin A is derived from provitamin A carotenoids, mainly beta-carotene, by beta-carotene 15,15'-monooxygenase (BCMO1; EC 1.13.11.21). We previously reported that chick duodenal BCMO1 activity increased abruptly just after hatching. In this study, we further investigated mechanisms and physiological roles of the postnatal induction of BCMO1 expression in the chick duodenum. We showed that BCMO1 mRNA levels increased in the chick duodenum during postnatal period after hatching, but remain unchanged in the chick liver throughout the perinatal period. Serum hydrocortisone (HC) levels were also increased after hatching. Moreover, HC-administered chicks showed an enhancement of duodenal BCMO1 mRNA during the perinatal period. We further analyzed the developmental gene expression patterns of three types of retinoic acid (RA) synthesizing enzymes in the chick duodenum. Among them, retinal dehydrogenase 1 (RALDH1) mRNA levels in the chick duodenum increased during the postnatal period, indicating a similar developmental expression pattern to that of BCMO1. These results suggest that the postnatal induction of BCMO1 gene expression in the chick duodenum may be caused by the elevation of serum HC levels and may contribute to the RALDH1-mediated RA synthetic pathway.

Diet-related variation in cellular retinol-binding protein type II gene expression in rat jejunum

Cellular retinol-binding protein type II (CRBPII) is involved in the transport of vitamin A and its metabolism in the small intestine. In the present study, we demonstrated diet-related variations in CRBPII expression in rat jejunum. The CRBPII protein and mRNA levels increased in parallel after the start of feeding period regardless of whether the feeding period was restricted to the hours of darkness or of light. In addition, this variation was observed in the rats fed high-fat diet or low-fat diets, but not in those fed a fat-free diet or in fasted rats. A similar diet-induced variation was seen in the mRNA of liver-type fatty acid-binding protein in rat jejunum. In the transient transfection experiment, unsaturated fatty acid increased rat CRBPII gene promoter activity via the PPARα/retinoid X receptor-α heterodimer. Taken together, these results suggest that the diet-related variation in CRBPII expression in rat jejunum may be brought about by the transcriptional induction of CRBPII gene expression mainly triggered by dietary fatty acids.

Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma

OBJECTIVE

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear hormone receptor superfamily. Treatment of PPARgamma ligands has been shown to inhibit the growth of various human cancer cells. However, it has not been reported whether human cervical carcinoma cells express PPARgamma. In this study, we investigated the expression of PPARgamma in human normal cervix and cervical carcinoma tissues, and as well as the effect of PPARgamma ligands on cervical cancer cells survival.

METHODS

Fresh cervical tissues from a study group of 10 study patients diagnosed with cervical carcinoma were analyzed for the expression of PPARgamma using real-time RT-PCR and Western blot analysis. Immunohistochemical staining for PPARgamma was also performed on the serial sections of 40 cervical carcinomas. In addition, we evaluated the feasibility of PPARgamma ligands, as a potential therapeutic drug against cervical cancer cells using MTT assay and FACS analysis.

RESULTS

We found that there were lower expression levels of PPARgamma mRNA and protein in cervical carcinoma tissues than in normal cervical tissues. The extent and intensity of immunoreactive PPARgamma in normal cervix tissues were statistically much greater than those of carcinoma tissues. In order to study effects of PPAR ligand on cell proliferation, we chose ciglitizone that showed very potent growth inhibitory effects on the proliferation of two human cervical cancer cell lines (C-33-A and C-4II). C-4II cells express high expression of PPARgamma, while C-33A cells express low level of PPARgamma. Treatment with ciglitizone inhibited the growth of C-4II cells in a dose-dependent manner, while the growth inhibitory effect of ciglitizone was much less in C-33A cells. In order to test whether ciglitizone-induced growth suppressive effects on cervical cancer cell lines is PPAR-dependent, we treated cervical cancer cells with ciglitizone and/or GW9662 (a PPARgamma antagonist). No significant difference in cell survival was found in cells treated with ciglitizone alone vs. co-treated with ciglitizone and GW9662. GW9662 alone did not induce any cell growth arrest in the cells that we used (data not shown). Thus, we concluded that growth suppressive effects by ciglitizone may not be dependent upon status of PPAR expression. To clarify the mechanism by which ciglitizone inhibits the growth of cervical carcinoma cells, flow cytometry and Western blotting assay were performed. As results, we demonstrated that a large portion of C-4II cells (but not in C-33A) after ciglitizone treatment were arrest at G1 phase with the induction of p21(Cip1/Waf1) and p27(kip1) protein.

CONCLUSIONS

These results suggest that PPARgamma is down-regulated in multiple human cervical cancer tissues and cell lines. Ciglitizone may suppress human cervical cancer cells in PPAR-independent manner.

Cellular retinol-binding protein type II (CRBPII) in adult zebrafish (Danio rerio). cDNA sequence, tissue-specific expression and gene linkage analysis

We have determined the nucleotide sequence of a zebrafish cDNA clone that codes for a cellular retinol-binding protein type II (CRBPII). Radiation hybrid mapping revealed that the zebrafish and human CRBPII genes are located in syntenic groups. In situ hybridization and emulsion autoradiography localized the CRBPII mRNA to the intestine and the liver of adult zebrafish. CRBPII and intestinal fatty acid binding protein (I-FABP) mRNA was colocalized to the same regions along the anterior-posterior gradient of the zebrafish intestine. Similarly, CRBPII and I-FABP mRNA are colocalized in mammalian and chicken intestine. CRBPII mRNA, but not I-FABP mRNA, was detected in adult zebrafish liver which is in contrast to mammals where liver CRBPII mRNA levels are high during development but rapidly decrease to very low or undetectable levels following birth. CRBPII and I-FABP gene expression appears therefore to be co-ordinately regulated in the zebrafish intestine as has been suggested for mammals and chicken, but CRBPII gene expression is markedly different in the liver of adult zebrafish compared to the livers of mammals. As such, retinol metabolism in zebrafish may differ from that of mammals and require continued production of CRBPII in adult liver. The primary sequence of the coding regions of fish and mammalian CRBPII genes, their relative chromosomal location in syntenic groups and possibly portions of the control regions involved in regulation of CRBPII gene expression in the intestine appear therefore to have been conserved for more than 400 million years.

Co-ordinated induction of beta-carotene cleavage enzyme and retinal reductase in the duodenum of the developing chicks

The developmental patterns of expression of beta-carotene cleavage enzyme activity were compared with those of retinal reductase and NAD-dependent retinol dehydrogenase activities in chick duodenum during the perinatal period. The beta-carotene cleavage enzyme activity was not detected in the duodenum before hatching, but it increased rapidly during 24 h after hatching. On the other hand, a considerable level of beta-carotene cleavage enzyme activity was observed in the liver of embryonic stages and its activity gradually rose during the perinatal period. Comparison of kinetic constants for the beta-carotene cleavage enzyme activities in the duodenum and the liver indicated that the enzyme in the duodenum possessed a lower affinity for beta-carotene than that in the liver. The retinal reductase activity was detected in the microsomes of the duodenum at the earliest time examined, i.e. day 16 of embryogenesis and its activity began to rise on the last day of embryogenesis, which was followed by a gradual increase until 1 day of age. The NAD-dependent retinol dehydrogenase activity was also seen in the microsomes of the duodenum in embryonic stages and its activity increased in parallel with the retinal reductase activity around the hatching period. These developmental inductions of beta-carotene cleavage enzyme and retinal reductase activities in the duodenum coincided with those of cellular retinol-binding protein, type II (CRBPII) and lecithin: retinol acyltransferase (LRAT). These results suggest that a co-ordinated induction mechanism should be operative for beta-carotene cleavage enzyme and retinal reductase, both of which are inevitable in the process of beta-carotene absorption and metabolism.

Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis

We report the isolation by RT-PCR of partial cDNAs encoding the human peroxisome proliferator-activated receptor (PPAR) isoforms PPARbeta and -gamma in human primary astrocytes (HPA) as well as in the human malignant astrocytoma cell line T98G. In contrast, we failed to detect PPARalpha mRNA in either of these two cell types. Because PPARbeta is ubiquitously expressed but has, as yet, no known function, we pursued our functional studies of these cells with regard to PPARgamma. To that end, we showed that PPARgamma protein is abundantly expressed in both cell types, having a molecular weight of approximately 50 kDa. Immunocytochemistry revealed a predominantly nuclear localization of this receptor. Moreover, incubation of the two cell types with 1-12 mcM 15-deoxy PGJ(2) or 1-12 mcM ciglitazone, both of which are agonists of PPARgamma, induced loss of cellular viability as assessed by the MTT assay after a 4 hr incubation. Reduced cellular viability as a consequence of exposure to PGJ(2) or ciglitazone resulted from induction of apoptosis, as assessed by DNA fragmentation and Hoechst staining, and involves activation of the CPP32 (caspase-3) protease. These data show that modulation of the process of apoptosis is one function of PPARgamma in cells derived from the human astrocytic lineage.